
CBE ID

3590

Title

Continuity of Care After Receiving Hospital or Residential Substance Use Disorder (SUD) Treatment

Endorsement Status

Endorsed

Is Under Review

No

Next Maintenance Cycle

Fall 2026

Previous Endorsement Cycle

Fall 2020

Initial Endorsement

Thu, 07/01/2021 - 00:00

Steward

RTI International

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

Percentage of Medicaid discharges, ages 18 to 64, being treated for a substance use disorder (SUD) from an inpatient or residential provider that received SUD follow-up treatment within 7 or 30 days after discharge. SUD follow-up treatment includes outpatient, intensive outpatient, or partial hospitalization visits; telehealth encounters; SUD medication fills or administrations; or residential treatment (after an inpatient discharge). Two rates are reported: continuity within 7 and 30 days after discharge.

1.7 Measure Type

Process

1.8 Level of Analysis

Facility

1.14 Numerator

Medicaid discharges, ages 18 to 64, with a principal/primary substance (SUD) diagnosis treated at an inpatient or residential provider that received SUD follow-up treatment within 7 or 30 days after discharge. SUD treatment includes outpatient, intensive outpatient, or partial hospitalization visits; telehealth encounters; or SUD medication fills or administrations; or residential treatment (after an inpatient discharge. Two rates are reported: continuity within 7 and 30 days after discharge.

1.15 Denominator

The denominator are Medicaid beneficiaries, ages 18-64, discharged from inpatient or residential provider with a principal diagnosis of SUD on the inpatient/residential treatment encounter claim.

1.20 Types of Data Sources

Claims Data

6.1.2 Current or Planned Use(s)

Quality Improvement with Benchmarking (external benchmarking to multiple organizations),
Quality Improvement (Internal to the specific organization)

6.1.3 Current Use(s)

Quality Improvement with Benchmarking (external benchmarking to multiple organizations),
Quality Improvement (Internal to the specific organization)

Exclusions

Dual eligible Medicare/Medicaid beneficiaries are excluded. Rationale: Individuals who are covered under Medicare would receive coverage for follow-up treatment medications (e.g. opioid use disorder medications) under Medicare Part D and Medicare Part D claims are not captured in Medicaid claims databases. Therefore follow-up treatment would be missed.

Measure Disclaimer

The performance measure, Continuity of Care After Receiving Hospital or Residential SUD Treatment, is not a clinical guideline and does not establish a standard of medical care and has not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

RTI International

Steward POC email

tmark@rti.org